NewsNovo
Moderna (NASDAQ:MRNA) shares climbed 6% to $239.74 in afternoon trading, outpacing peers BioNTech SE and Pfizer as capital shifts away from artificial intelligence names.
The move highlights a broader rotation into healthcare, with Moderna leading the sector despite the absence of a new company announcement.
The divergence in performance underscores the concentration of buying in the mRNA developer. While Moderna gained 6%, BioNTech stock rose 2% to $90.10, and Pfizer stock increased 2% to $29.65.
Both peers trailed Moderna by a significant margin, suggesting the rally is driven by specific factors affecting the company rather than a uniform lift across the entire healthcare group.
Keep reading